ClinicalTrials.gg
RecruitingNCT06557044PENGUpdated Aug 16, 2024

The Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block in Patients Undergoing Primary Total Hip Arthoplasty:

An interventional study of Ropivacaine and Physiological saline in Prospective, Randomized and Double-blind, sponsored by Diakonie-Klinikum Stuttgart. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Diakonie-Klinikum Stuttgart · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Mar 2024, registered Aug 2024).
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to investigate the analgesic efficacy of the pericapsular nerve group (PENG) block during the implantation of hip endoprostheses. The study is designed as a prospective randomized double-blind study and the study participants were randomized into 2 arms and either 20 ml ropivacaine 0.5% (verum group) or 20 ml physiological saline solution (placebo group) will be applied.

02

Conditions studied

  • Prospective
  • Randomized
  • Double-blind

Keywords

  • Pericapsular Nerve Group Block
  • hip endoprostheses
03

In context

Lead sponsor

Diakonie-Klinikum Stuttgart is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • planned cementless hip TEP operation for primary coxarthrosis via minimally invasive anterolateral approach using the identical implant system (Taperloc stem, Plamafit cup)
  • Patient capable of giving consent
  • has been obtained
  • age > 18 years

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study
  • Regular use of opioids
  • Known chronic pain symptoms
  • Infections in the area of the puncture site
  • Presence of a to ropivacaine
  • Presence of a contraindication to metamizole
  • Presence of a contraindication to postoperative analgesia with diclofenac
  • Secondary forms of osteoarthritis with deformities (i.e. high-grade dysplasia, secondary conditions after trauma, secondary conditions after childtrauma, secondary conditions after childhood hip joint diseases
  • Spinopelvic dysbalance, spinal canal stenosis
  • Previous operations on the hip/pelvis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Verum Group

    20 ml ropivacaine 0.5%

    Drug: Ropivacaine

  • Placebo comparator
    Placebo Group

    20 ml physiological saline

    Other: Physiological saline

Interventions

  • PENG block with ropivacaine

  • OtherPhysiological saline

    Placebo control

06

What researchers measure

Primary outcomes

  1. Rate of postoperative opioid administration

    The primary objective is to investigate the influence of the PENG block on the need for postoperative ntravenously opioid administration within the first hour in the recovery room.

    Time frame: 60 minutes after arrival in the recovery room

Secondary outcomes

  1. Quantity of total opioid consumption

    Assessment of total opioid consumption until second postoperative day in both arms

    Time frame: until the evening of the second postoperative day

  2. Intensity of postoperative pain

    Subjective perception of postoperative pain, using the numeric rating scale.

    Time frame: until the evening of the second postoperative day

  3. Intensity of postoperative nausea and vomiting

    Assessment of postoperative nausea/vomiting using the PONV Score

    Time frame: until the evening of the second postoperative day

  4. Postoperative recovery

    Assessment of postoperative recovery using the QoR15 score

    Time frame: until the evening of the second postoperative day

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Mar 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 16, 2024
StartActual
Mar 7, 2024
Primary completionEst.
Mar 2025
CompletionEst.
Mar 2025
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06557044
Lead sponsor
Diakonie-Klinikum Stuttgart
Responsible party
Prof. Dr. Rainer Meierhernich (Principal Investigator, Diakonie-Klinikum Stuttgart) — Principal investigator
First posted
Aug 16, 2024
Start date
Mar 7, 2024
Primary completion
Mar 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Aug 16, 2024

Study contacts

Rainer Meierhenrich, Prof. Dr.
Contact
meierhenrich@diak-stuttgart.de
00497119912290

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion